Daxor Corp
NASDAQ:DXR
Intrinsic Value
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. [ Read More ]
The intrinsic value of one DXR stock under the Base Case scenario is 3.42 USD. Compared to the current market price of 8.57 USD, Daxor Corp is Overvalued by 60%.
Valuation Backtest
Daxor Corp
Run backtest to discover the historical profit from buying and selling DXR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Daxor Corp's business.
What risks and challenges
does Daxor Corp face in the near future?
Summarize the latest earnings report
of Daxor Corp.
Provide P/E
for Daxor Corp and its competitors.
Balance Sheet Decomposition
Daxor Corp
Current Assets | 25.9k |
Receivables | 25.9k |
Non-Current Assets | 34.8m |
Long-Term Investments | 34.8m |
Current Liabilities | 858.8k |
Accounts Payable | 103.1k |
Short-Term Debt | 755.7k |
Earnings Waterfall
Daxor Corp
Revenue
|
163.4k
USD
|
Cost of Revenue
|
-809.5k
USD
|
Gross Profit
|
-646.1k
USD
|
Operating Expenses
|
-239.5k
USD
|
Operating Income
|
-885.6k
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
280.6k
USD
|
Free Cash Flow Analysis
Daxor Corp
What is Free Cash Flow?
DXR Profitability Score
Profitability Due Diligence
Daxor Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Daxor Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
DXR Solvency Score
Solvency Due Diligence
Daxor Corp's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Daxor Corp's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DXR Price Targets Summary
Daxor Corp
According to Wall Street analysts, the average 1-year price target for DXR is 24.48 USD with a low forecast of 24.24 USD and a high forecast of 25.2 USD.
Ownership
DXR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DXR Price
Daxor Corp
Average Annual Return | -4.23% |
Standard Deviation of Annual Returns | 25.52% |
Max Drawdown | -70% |
Market Capitalization | 41.2m USD |
Shares Outstanding | 4 792 320 |
Percentage of Shares Shorted | 0.36% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The Company’s investment objectives are capital preservation, maintaining returns on capital with a high degree of safety and generating income from dividends and option sales to help offset operating losses from the Company’s operating division. The firm intends to maintain a diversified securities portfolio comprised primarily of electric utility company common and preferred stocks. The firm seeks to maintain a minimum of 80% of its portfolio in equity securities of utility companies.
Contact
IPO
Employees
Officers
The intrinsic value of one DXR stock under the Base Case scenario is 3.42 USD.
Compared to the current market price of 8.57 USD, Daxor Corp is Overvalued by 60%.